To determine the role of cross-presenting cDC1s in the efficacy of the Flt3L+NDV treatment, GFP+ A20 tumor-bearing Wt or Batf3-/- mice were treated as previously described (Fig. 3a). This evidence concerns the gene BATF3 and neoplasm.